Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Studie som testar två konditioneringsregimer med en enda profylax av GVHD med cyklofosfamid och metotrexat efter transplantation hos patienter som är kvalificerade för allografttransplantation med matchad donator (CY-MET-RIC)

16 november 2026 uppdaterad av: Nantes University Hospital

Randomiserad fas 2-studie som testar två konditioneringsregimer med en enda profylax av graft-versus-host-sjukdom med cyklofosfamid och metotrexat efter transplantation hos patienter som är kvalificerade för allografttransplantation med matchad donator

Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-CSH).

Recently, in the context of semi-identical (=haploidentical) HLA donors, but also of compatible HLA donors, the use of cyclophosphamide (CY) administered in high doses at early post-transplant (PT) (=PTCY) (Days +3 and +4 or +5) has shown excellent control of acute and chronic GVH, even enabling the discontinuation of other immunosuppressive drugs administered after allo-CSH (ciclosporin, mycophenolate mofetyl (MMF) or Cellcept).

This step has already been taken in the context of allo-CSH with myeloablative conditioning (MAC), which is a minoritary conditioning in adults.

However, in the context of allo-CSH with reduced-intensity conditioning (RIC), which predominates in adults, this strategy seems insufficient to prevent the risk of GVHD.

The idea of reducing the use of immunosuppressants in the context of RIC/HLA-compatible transplants seems, however, still relevant, in order to reduce their adverse effects, improve patients' quality of life and enhance the reconstitution of the post-transplant immune system.

Studieöversikt

Detaljerad beskrivning

For this reason, the investigators now wish to test the administration of a combination of a high dose of early post-transplant CY (PTCY) and methotrexate (MTX) on days (D) D+1, D+4, D+6, D+11 (doses already performed in MAC transplant prophylaxis), with anti-lymphocyte serum (ALS) with RIC conditioning, without ciclosporin or MMF.

The investigators hypothesize that administration of this PTCY+MTX combination will enable immunosuppressive drugs to be discontinued as early as D+11 post-transplant, compared with the usual average of 3 to 4 months.

Studietyp

Interventionell

Inskrivning (Beräknad)

82

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 70 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age: ≥ 18 and ≤ 70 years old
  • Patient with hematologic malignancy
  • Indication for HSC allograft with attenuated conditioning
  • Pluripotent stem cell (PSC) engraftment
  • Availability of a 10/10 familial or non-familial HLA compatible donor
  • Consent to the protocol
  • ECOG <=2
  • Woman of childbearing age with negative pregnancy test and on highly effective contraception during treatment and for a period of 12 months after stopping MTX and CY
  • Man of childbearing age with highly effective contraception during treatment and for a period of 6 months after stopping MTX and CY and a period of 12 months after stopping MTX and CY if TBF conditioning regimen arm
  • Negative Hepatitis B, C, HIV serologies
  • Social security affiliation

Exclusion Criteria:

  • History of allograft
  • Patient eligible for myeloablative conditioning (MAC)
  • Bone marrow transplant
  • Other progressive cancerous disease, or antecedent of cancer in the last five years, with the exception of a carcinoma of the skin or a carcinoma in situ of the uterine cole treated and in remission.
  • Progressive psychiatric condition
  • Pregnant or breastfeeding woman,
  • Woman or man of childbearing age with lack of effective contraception
  • Serious and uncontrolled concomitant infection
  • Cardiac: systolic ejection fraction < 50% by transthoracic ultrasound or by isotopic method (isotope gamma angiography), NYHA II, III or IV heart failure, active rhythmic, valvular or ischemic heart disease or anteriority
  • Respiratory with EFR: DLCOc <40% of theoretical
  • Renal: creatinine clearance < 50 ml/min (assessment with MDRD method)
  • Urological: active urinary tract infection, history of acute urothelial toxicity due to cytotoxic chemotherapy or radiotherapy, known obstruction of urinary flow, pre-existing hemorrhagic cystitis
  • Hepatic: transaminases greater than 5 times normal or bilirubin greater than 2 times normal
  • Person protected by law (major under guardianship, curatorship or legal protection)
  • Vaccination against yellow fever in the last year
  • Known or suspected hypersensitivity to rabbit proteins as well as to the active substance and excipients of all investigational and ancillary drugs administered during the study,
  • Contraindication to any of the investigational or adjuvant drugs administered during the study
  • Patient not speaking French

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: (CLO)-BALTIMORE

BALTIMORE conditioning regime for LYMPHOID HEMOPATHY CLO-BALTIMORE conditioning regime for MYELOID HEMOPATHY

15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)

Andra namn:
  • MTX

50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)

Andra namn:
  • CY

Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)

Andra namn:
  • Fludarabin Baltimore

Conditioning regimen: 14.5 mg/kg intravenous 2 days on Day-6/Day-5 before graft (=Day0)

Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)

Andra namn:
  • ATG

2 grays on Day-1 before graft (=Day0)

Andra namn:
  • TBI

High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)

Andra namn:
  • HSC

Graft nuclear cells CD3+ cells if needed after transplantation

DLI with CD3+ if relapse after transplantation or in prevention of relapse

Andra namn:
  • DLI

Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)

Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)

Andra namn:
  • Fludarabin TBF
Aktiv komparator: TBF

Conditioning regimen for LYMPHOID AND MYELOID HEMOPATHY

15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)

Andra namn:
  • MTX

50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)

Andra namn:
  • CY

Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)

Andra namn:
  • Fludarabin Baltimore

Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)

Andra namn:
  • ATG

High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)

Andra namn:
  • HSC

Graft nuclear cells CD3+ cells if needed after transplantation

DLI with CD3+ if relapse after transplantation or in prevention of relapse

Andra namn:
  • DLI

Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)

Andra namn:
  • Fludarabin TBF

Conditioning regimen: 5 mg/kg Intravenous at Day-6 before graft (=Day0)

Conditioning regimen: 3.2 mg/kg Intravenous 2 days at Day-2 and Day-1 before graft (=Day0)

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of grade 3-4 acute GVHD following allo-CSH for all patients and for each conditioning group (Baltimore and TBF).
Tidsram: Post-transplant through study completion, an average of 1 year

Estimation of the incidence of grade 3 and 4 acute GVHD following allo-CSH (excluding post-DLI* acute GVHD) according to Mount Sinai criteria.

Post-transplant through study completion, an average of 1 year

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of engraftment
Tidsram: Month 1 post-transplant

Engraftment assessed on hematological reconstitution (number of days of aplasia with PNN <0.5 G/L and platelets < 20 G/L, number of platelet and red cell concentrate transfusions)

Month 1 post-transplant
Overall survival (OS)
Tidsram: Post-transplant through study completion, an average of 1 year

survival between day 0 of transplantation and date of death or last follow-up

Post-transplant through study completion, an average of 1 year
Disease-free survival (DFS)
Tidsram: Post-transplant through study completion, an average of 1 year

survival between day 0 of transplantation and date of relapse, death or last follow-up

Post-transplant through study completion, an average of 1 year
GVHD and relapse-free survival (GRFS)
Tidsram: Post-transplant through study completion, an average of 1 year

relapse-free survival without grade 3-4 acute GVHD or chronic GVHD requiring systemic treatment

Post-transplant through study completion, an average of 1 year
Incidence of acute GVHD grade 2-4
Tidsram: Post-transplant through study completion, an average of 1 year

Acute GVH grade 2-4 according to Mount Sinai criteria

Post-transplant through study completion, an average of 1 year
Incidence of chronic GVHD
Tidsram: From month 3 post-transplant through study completion, an average of 1 year

Chronic GVHD according to NCI criteria

From month 3 post-transplant through study completion, an average of 1 year
Incidence of corticoresistant acute GVHD
Tidsram: Post-transplant through study completion, an average of 1 year

Acute corticoresistant GVHD according to the criteria of Mohty et al. defined by :

  • worsening/progression of disease after 3 days of 2mg/kg/day systemic corticosteroid therapy with methylprednisolone (or equivalent),
  • non-improvement of disease after 7 days of 2mg/kg/day systemic corticosteroid therapy with methylprednisolone (or equivalent),
  • disease progression to a new organ after treatment with 1mg/kg/day methylprednisolone (or equivalent) in the case of cutaneous or gastrointestinal GVHD or,
  • recurrence of acute GVHD during or after the corticosteroid reduction phase
Post-transplant through study completion, an average of 1 year
Incidence of non-relapse mortality (NRM)
Tidsram: Post-transplant through study completion, an average of 1 year

any death unrelated to relapse or disease progression

Post-transplant through study completion, an average of 1 year
Incidence of relapse
Tidsram: Post-transplant through study completion, an average of 1 year

any documented disease recurrence

Post-transplant through study completion, an average of 1 year
Chimerism
Tidsram: At Month1, Month2, Month3, Month6, Month12 post-transplant

Total donor or mixed chimerism. Total donor chimerism = result >95% donor CD3+ cells. Mixed chimerism = result >5% and <95% donor CD3+ cells.

At Month1, Month2, Month3, Month6, Month12 post-transplant
Immune reconstitution
Tidsram: At Month3, Month6, Month9, Month12 post-transplant

T, NK, B lymphocytes and monocytes

At Month3, Month6, Month9, Month12 post-transplant
Grade 3 and 4 post-transplant adverse events
Tidsram: Post-transplant through study completion, an average of 1 year

Grade 3 and 4 post-transplant adverse events (dates of occurrence) (NCI CTCAE criteria, version number 5)

Post-transplant through study completion, an average of 1 year
Incidence of viral, bacteriological, fungal and parasitic infections
Tidsram: Post-transplant through study completion, an average of 1 year

Infections: viral (CMV, EBV, BKV, adenovirus), bacteriological, fungal and parasitic

Post-transplant through study completion, an average of 1 year

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Marie-Anne COUTURIER, MD, University Hospital, Brest
  • Huvudutredare: Sylvain THEPOT, MD, University Hospital, Angers

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

18 juli 2024

Primärt slutförande (Beräknad)

18 oktober 2029

Avslutad studie (Beräknad)

18 juli 2030

Studieregistreringsdatum

Först inskickad

24 januari 2024

Först inskickad som uppfyllde QC-kriterierna

1 februari 2024

Första postat (Faktisk)

12 februari 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

19 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 november 2026

Senast verifierad

1 november 2026

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera